Compare Inovio Pharmaceuticals Inc (INO) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ON Holding AG — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while ON Holding AG trades at $35.09 (market cap $11.38B). The key difference: ON Holding AG is far larger — about 101.4× Inovio Pharmaceuticals Inc's market cap, and ON Holding AG is more actively traded (13,732,872 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and ON Holding AG for 22 Days on average.
| INO | ONON | |
|---|---|---|
Market Cap | $112.19M | $11.38B |
Volume | 3,201,278 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $2.60 | $50.63 |
52-Week Low | $0.66 | $26.76 |
Typical Hold Time | 43 Days | 22 Days |
Enterprise Value | $83.51M | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
ONON trades at $34.04, up 2.47% today, with strong bullish technical signals from moving averages and recent positive earnings momentum. The company reported Q2 2026 EPS of $0.44, beating expectations of $0.42, continuing a pattern of quarterly beats. Fundamental strength is evident with 64.82% gross margins and 23.95% ROE, while analyst consensus remains strongly bullish with a $42.26 price target representing 24% upside potential.
The outlook remains positive given strong DTC growth, premium store expansion, and a newly announced $1 billion buyback program through 2029. Key risks include competitive pressures in footwear and potential margin compression from expansion costs. The stock appears reasonably valued at 24x P/E given its growth trajectory and profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
